Venous Thromboembolism and Antithrombotic Therapy in Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 36, Issue 6, 2014, Pages 527-553

  Chan, Wee Shian ^a   Rey, Evelyne ^a   Kent, Nancy E ^a   Corbett, Thomas ^a   David, Michèle ^a   Douglas, M Joanne ^a   Gibson, Paul S ^a   Magee, Laura ^a   Rodger, Marc ^a   Smith, Reginald E ^a  

^a NONE   (Canada)

Author keywords

Adverse pregnancy outcomes; Assisted reproductive technology; Deep vein thrombosis; Heparin; Neuraxial analgesia; Pregnancy or puerperal complications; Pulmonary embolism; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; FIBRINOLYTIC AGENT;

ANESTHESIA; ARTICLE; BLOOD CLOT LYSIS; CEREBRAL SINUS THROMBOSIS; CLINICAL PRACTICE; COMPRESSION STOCKING; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; INFERTILITY THERAPY; MATERNAL MORBIDITY; NEURAXIAL ANAESTHESIA; OVARIAN VEIN; OVARIAN VEIN THROMBOSIS; PATIENT CARE; PATIENT MONITORING; PERINATAL PERIOD; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; SUPERFICIAL THROMBOPHLEBITIS; SYSTEMATIC REVIEW (TOPIC); THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; ADVERSE PREGNANCY OUTCOMES; ALGORITHM; ASSISTED REPRODUCTIVE TECHNOLOGY; DEEP VEIN THROMBOSIS; FEMALE; LUNG EMBOLISM; NEURAXIAL ANALGESIA; PREGNANCY OR PUERPERAL COMPLICATIONS; THROMBOPROPHYLAXIS;

ADVERSE PREGNANCY OUTCOMES; ASSISTED REPRODUCTIVE TECHNOLOGY; DEEP VEIN THROMBOSIS; HEPARIN; NEURAXIAL ANALGESIA; PREGNANCY OR PUERPERAL COMPLICATIONS; PULMONARY EMBOLISM; THROMBOPROPHYLAXIS; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ALGORITHMS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; VENOUS THROMBOEMBOLISM;

EID: 84908070920     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30569-7     Document Type: Article

References (187)

1. Liu S., Rouleau J., Joseph K.S., Sauve R., Liston R., Young D., et al. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can 2009, 31:611-620.
2. Lindqvist P., Dahlback B., Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999, 94:595-599.
3. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008, 198:233.e1-233.e7.
4. Sultan A.A., Tata L., West J., Fiaschi L., Fleming K., Nelson-Piercy C., et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013, 121:3953-3961.
5. Sultan A.A., West J., Tata L.J., Fleming K., Nelson-Piercy C., Grainge M.J. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. BJH 2011, 156:366-373.
6. Virkus R.A., Lokkegaard E.C.L., Bergholt T., Mogensen U., Langhoff-Roos J., Lidegaard O. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. Thromb Haemost 2011, 106:304-309.
7. Heit J.A., Kobbervig C.E., James A.H., Petterson T.M., Bailey K.R., Melton L.J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005, 143:697-706.
8. Bates S.M., Jaeschke R., Stevens S.M., Goodacre S., Wells P.S., Stevenson M.D., et al. Diagnosis of DVT. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e351S-e418S.
9. Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., Vandvik P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e691S-e736S.
10. Horlocker T.T., Wedel D.J., Rowlingson J.C., Enneking F.K., Kopp S.L., Benzon H.T., et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition). Reg Anesth Pain Med 2010, 35:64-101.
11. Nelson-Piercy C., MacCallum P., Mackillop L. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top guideline no. 37a 2009, Royal College of Obstetricians and Gynaecologists, London.
12. Greer I.A., Thomson A.J. The acute management of thrombosis and embolism during pregnancy and the puerperium. Green-top guideline no. 37b 2007, Royal College of Obstetricians and Gynaecologists, London.
13. McLintock C., Brighton T., Chunilal S., Dekker G., McDonnell N., McRae S., et al. Councils of the Society of Obstetric Medicine of Australia and New Zealand Australasian Society of Thrombosis and Haemostasis. Recommendations for the prevention of pregnancy- associated venous thromboembolism. Aust N Z J Obstet Gynaecol 2012, 52:3-13.
14. McLintock C., Brighton T., Chunilal S., Dekker G., McDonnell N., McRae S., et al. Councils of the Society of Obstetric Medicine of Australia and New Zealand Australasian Society of Thrombosis and Haemostasis. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol 2012, 52:14-22.
15. Lindqvist P.G., Hellgren M. Obstetric thromboprophylaxis: the Swedish guidelines. Adv Hematol 2011, 2011:1-6. 10.1155/2011/157483.
16. Macklon N.S., Greer I.A., Bowman A.W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynecol 1997, 104:191-197.
17. Ray J.G., Chan W.S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999, 54:265-271.
18. Chan W.S., Spencer F.A., Ginsberg J.S. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 2010, 182(7):657-660.
19. To M.S., Hunt B.J., Nelson-Piercy C. A negative D-dimer does not exclude venous thromboembolism in pregnancy. J Obstet Gynaecol 2008, 28:222-223.
20. Damodaram M., Kaladindi M., Luckit J., Yoong W. D-dimers as a screening test for venous thromboembolism in pregnancy: is it of any use?. J Obstet Gynaecol 2009, 29:101-103.
21. Chan W.S., Chunilal S., Lee A., Crowther M., Rodger M., Ginsberg J.S. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med 2007, 147:165-170.
22. Chan W.S., Lee A., Spencer F.A., Crowther M., Rodger M., Ramsay T., et al. Predicting deep venous thrombosis in pregnancy: out in "LEFt" field?. Ann Intern Med 2009, 151:85-92. Erratum in: Ann Intern Med 2009;151:516.
23. Chan W.S., Lee A., Spencer F.A., Chunilal S., Crowther M., Wu W., et al. D-dimer testing in pregnant patients: towards determining the next 'level' in the diagnosis of deep vein thrombosis. J Thromb Haemost 2010, 8:1004-1011.
24. Le Gal G., Kercret G., Ben Yahmed K., Bressollette L., Robert-Ebadi H., Riberdy L., et al. Diagnostic value of single complete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: a prospective study. BMJ 2012, 344. EDVIGE Study Group. 10.1136/bmj.e2635.
25. Fraser D.G., Moody A.R., Morgan P.S., Martel A.L., Davidson I. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002, 136:89-98.
26. Sampson F.C., Goodacre S.W., Thomas S.M., van Beek E.J. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol 2007, 17:175-181.
27. Ginsberg J.S., Hirsh J., Rainbow R.J., Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal thromboembolic disease. Thromb Haemost 1989, 61:189-196.
28. Doll R., Wakefield R. Risk of childhood cancer from fetal radiation. Br J Rad 1997, 70:130-139.
29. Hurwitz L.M., Yoshizumi T., Reiman R.E., Goodman P.C., Paulson E.K., Frush D.P., et al. Radiation dose to the fetus from body MDCT during early gestation. Am J Roentgenol 2006, 186:871-876.
30. Cook J.V., Kyriou J. Radiation from CT and perfusion scanning in pregnancy. BMJ 2005, 331:350.
31. Parker M.S., Hui F.K., Camacho M.A., Chung J.K., Broga D.W., Sethi N.N. Female breast radiation exposure during CT pulmonary angiography. Am J Roentgenol 2005, 185:1228-1233.
32. Berrington de Gonzalez A., Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004, 363:345-351.
33. Bourjeily G., Chalhoub M., Phornphutkul C., Alleyne T.C., Woodfield C.A., Chen K.K. Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero. Radiology 2010, 256:744-750.
34. Chan W.S., Ray J.G., Murray S., Coady G.E., Coates G., Ginsberg J.S. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med 2002, 162:1170-1175.
35. Scarsbrook A.F., Bradley K.M., Gleeson F.V. Perfusion scintigraphy: diagnostic utility in pregnant women with suspected pulmonary embolic disease. Eur Radiol 2007, 17:2554-2560.
36. Cahill A.G., Stout M.J., Macones G.A., Bhalla S. Diagnosing pulmonary embolism in pregnancy using computed-tomographic angiography or ventilation-perfusion. Obstet Gynecol 2009, 114:124-129.
37. Shahir K., Goodman L.R., Tali A., Thorsen K.M., Hellman R.S. Pulmonary embolism in pregnancy: CT pulmonary angiography versus perfusion scanning. Am J Roentgenol 2010, 195:214-220.
38. Bourjeily G., Khalil H., Raker C., Martin S., Auger P., Chalhoub M., et al. Outcomes of negative multidetector computed tomography with pulmonary angiography in pregnant women suspected of pulmonary embolism. Lung 2012, 190:105-111.
39. Anderson D.R., Kahn S.R., Rodger M.A., Kovacs M.J., Morris T., Hirsch A., et al. Computed tomographic pulmonary angiography vs ventilation- perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 2007, 298:2743-2753.
40. U-King-Im J.M., Freeman S.J., Boylan T., Cheow H.K. Quality of CT pulmonary angiography for suspected pulmonary embolus in pregnancy. Eur Radiol 2008, 18:2709-2715.
41. Ridge C.A., McDermott S., Freyne B.J., Brennan D.J., Collins C.D., Skehan S.J. Pulmonary embolism in pregnancy: comparison of pulmonary CT angiography and lung scintigraphy. Am J Roentgenol 2009, 193:1223-1227.
42. Ridge C.A., Mhuircheartaigh J.N., Dodd J.D., Skehan S.J. Pulmonary CT angiography protocol adapted to the hemodynamic effects of pregnancy. Am J Roentgenol 2011, 197:1058-1063.
43. Bourjeily G., Paidas M., Khalil H., Rosene-Montella K., Rodger M. Pulmonary embolism in pregnancy. Lancet 2010, 375:500-512.
44. Ginsberg J.S., Hirsch J., Turner D.C., Levine M.N., Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989, 61:197-203.
45. Pauli R.M., Haun J. Intrauterine effects of coumarin derivatives. Dev Brain Dysfunct 1993, 6:229-247.
46. Chan W.S., Anand S., Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systemic review of the literature. Arch Intern Med 2000, 160:191-196.
47. Flessa H.C., Kapstrom A.B., Glueck H.I., Will J.J. Placental transport of heparin. Am J Obstet Gynecol 1965, 93:570-573.
48. Forestier F., Daffos F., Capella-Pavlovsky M. Low molecular weight heparin (PK10169) does not cross the placenta during second trimester of pregnancy; study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34:557-560.
49. Lepercq J., Conard J., Borel-Derlon A., Darmon J.Y., Boudignat O., Francoual C., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001, 108:1134-1140.
50. Rodie V.A., Thomson A.J., Stewart F.M., Quinn A.J., Walker I.D., Greer I.A. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG 2001, 109:1020-1024.
51. Greer I.A., Nelson-Piercy C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systemic review of safety and efficacy. Blood 2005, 106:401-407.
52. Ni Ainle F.N., Wong A., Appleby N., Byrne B., Regan C., Tayyaba H., et al. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 2008, 19:689-692.
53. Linkins L.-A., Dans A.L., Moores L.K., Bona R., Davidson B.L., Schulmans S., et al. Treatment and prevention of heparin-induced thrombocytopenia. Chest 2012, 141:e495S-e530S.
54. Schindewolf M., Mosch G., Bauersachs R.M., Lindhoff-Last E. Safe anticoagulation with danaparoid in pregnancy and lactation. Thromb Haemost 2004, 92:211.
55. Mazzolai L., Hohlfeld P., Spertini F., Hayoz D., Schapira M., Duchosal M.A. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006, 108:1569-1570.
56. Sarig G., Brenner B. Monitoring of low molecular weight heparin (LMWH) in pregnancy. Thrombosis Res 2005, 115(Suppl 1):84-86.
57. Barbour L.A., Oja J.L., Schultz L.K. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004, 191:1024-1029.
58. Norris L.A., Bonnar J., Smith M.P., Steer P.J., Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy: a pharmacokinetic study. Thromb Haemost 2004, 92:791-796.
59. Smith M.P., Norris L.A., Steer P.J., Savidge G.F., Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004, 190:495-501.
60. Kahn S.R., Ginsberg J.S. The post thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002, 16:155-165.
61. Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e419S-e494S.
62. Kahn S.R., Shapiro S., Wells P.S., Rodger M.A., Kovacs M.J., Anderson D.R., et al. A multicenter randomized placebo controlled trial of compression stockings to prevent the post-thrombotic syndrome after proximal deep venous thrombosis: The S.O.X. Trial. Blood (ASH Annual Meeting Abstracts) 2012, 120:393.
63. Turrentine M.A., Braema G., Ramirez M.M. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995, 50:534-541.
64. Leonhardt G., Gaul C., Nietsch H.H., Buerke M., Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006, 21:271-276.
65. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du risque d'embolie pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409-415.
66. Aburahma A.F., Mullins D.A. Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity. J Vasc Surg 2001, 33:375-378.
67. Kawamata K., Chiba Y., Tanaka R., Higashi M., Nishigami K. Experience of temporary inferior vena cava filters inserted in the perinatal period to prevent pulmonary embolism in pregnant women with deep vein thrombosis. J Vasc Surg 2005, 41:652-656.
68. Milford W., Chadha Y., Lust K. Use of a retrievable vena cava filter in term pregnancy: case report and review of the literature. Aust N Z J Obstet Gynaecol 2009, 49:331-333.
69. Lanska D.J., Kryscio R.J. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000, 31:1274-1282.
70. Cantu-Brito C., Arauz A., Aburto Y., Barinagarrementeria F., Ruiz-Sandoval J.L., Baizabal-Carvallo J.F. Cerebrovascular complications during pregnancy and postpartum: clinical and prognosis observations in 240 Hispanic women. Eur J Neurol 2011, 18:819-825.
71. Saposnik G., Barinagarrementeria F., Brown R.D., Bushnell C.D., Cucchiaron B., Cushman M., et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:1158-1192.
72. McColl M.D., Ramsay J.E., Tait R.C., Walker I.D., McCall F., Conkie J.A., et al. Superficial vein thrombosis: incidence in association with pregnancy and prevalence of thrombophilic defects. Thromb Haemost 1998, 79:741-742.
73. Lutter K.S., Kerr T.M., Roedersheimer L.R., Lohr J.M., Sampson M.G., Cranley J.J. Superficial thrombophlebitis diagnosed by duplex scanning. Surgery 1991, 110:42-46.
74. Gorty S., Patton-Adkins J., DaLanno M., Starr J., Dean S., Satiani B. Superficial venous thrombosis of the lower extremities: analysis of risk factors, and recurrence and role of anticoagulation. Vasc Med 2004, 9:1-6.
75. Wichers I.M., Di Nisio M., Buller H.R., Middeldorp S. Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica 2005, 90:672-677.
76. Decousus H., Prandoni P., Mismetti P., Bauersachs R., Boda Z., Brenner B., et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010, 363:1222-1232.
77. Di Nisio M., Wichers I.M., Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2012, 3.
78. Brown C.E., Stettler R.W., Twickler D., Cunningham F.G. Puerperal septic pelvic thrombophlebitis: incidence and response to heparin therapy. Am J Obstet Gynecol 1999, 181:143-148.
79. Salomon O., Dulitzky M., Apter S. New observations in postpartum ovarian vein thrombosis: experience of single center. Blood Coagul Fibrinolysis 2010, 21:16-19.
80. Dunnihoo D.R., Gallaspy J.W., Wise R.B., Otterson W.N. Postpartum ovarian vein thrombophlebitis: a review. Obstet Gynecol Surv 1991, 46:415-427.
81. Twickler D.M., Setiawan A.T., Evans R.S., Erdman W.A., Stettler R.W., Brown C.E., et al. Imaging of puerperal septic thrombophlebitis: prospective comparison of MR imaging, CT, and sonography. Am J Roentgenol 1997, 169:1039-1043.
82. Garcia J., Aboujaoude R., Apuzzio J., Alvarez J.R. Septic pelvic thrombophlebitis: diagnosis and management. Infect Dis Obstet Gynecol 2006, 2006:15614.
83. Chen KT. Septic pelvic thrombophlebitis. Available at: . Accessed on September 15, 2012. http://www.uptodate.com.
84. Kominiarek M.A., Hibbard J.U. Postpartum ovarian vein thrombosis: an update. Obstet Gynecol Surv 2006, 61:337-342.
85. Ho W.K., Hankey G.J., Eikelboom J.W. Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. Med J Aust 2011, 195:139-142.
86. Dalen J.E. Should patients with venous thromboembolism be screened for thrombophilia?. Am J Med 2008, 121:458-463.
87. Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis 2011, 31:275-281.
88. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practive guidelines (8 th Edition). Chest 2008, 133:381S-453S.
89. Brill-Edwards P., Ginsberg J.S., Gent M., Hirsh J., Burrows R., Kearon C., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med 2000, 343:1439-1444.
90. Pabinger I., Grafenhofer H., Kaider A., Kyrle P.A., Quehenberger P., Mannhalter C., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005, 3:949-954.
91. De Stefano V., Martinelli I., Rossi E., Battaglioli T., Za T., Mannuucci P.M., et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006, 135:386-391.
92. White R.H., Chan W.S., Zhou H., Ginsberg J.S. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost 2008, 100:246-252.
93. Meinardi J.R., Middeldorp S., de Kam P.J., Koopman M.M., van Pampus E.C.M., Hamulyak K., et al. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. Blood Coagul Fibrinolysis 2001, 12:713-720.
94. Samama M.M., Rached R.A., Horellou M.H., Aquilanti S., Mathieux V.G., Plu-Burean G., et al. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. Br J Haematol 2003, 123:327-334.
95. Rodeghiero F., Tosetto A. The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thromb Haemost 1997, 78:636-640.
96. Jacobsen A.F., Dahm A., Bergrem A., Jacobsen E.M., Sandset P.M. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 2010, 8:2443-2449.
97. Middeldorp S., Henkens C.M.A., Koopman M.M.W., van Pampus E.C.M., Hamulyak K., Van der Meer J., et al. The incidence of venous thromboembolism in family members of patients with Factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998, 128:15-20.
98. Zotz R.B., Gerhardt A., Scharf R.E. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003, 16:243-259.
99. McColl M.D., Ramsay J.E., Tait R.C., Walker I.D., McCall F., Conkie J.A., et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997, 78:1183-1188.
100. Pabinger I., Nemes L., Rintelen C., Koder S., Lechler E., Loreth R., et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000, 1:37-41.
101. Middeldorp S., Libourel E.J., Hamulyak K., Van der Meer J., Buller H.R. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001, 113:553-555.
102. Martinelli I., Battaglioli T., De Stefano V., Tormene D., Valdre L., Grandone E., et al. The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost 2008, 6:494-498.
103. Folkeringa N., Brouwer J.L.P., Korteweg F.J., Veeger N.J.G.M., Erwich J.J.H.M., Van Der Meer J. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol 2007, 138:110-116.
104. Ruiz-Irastorza G., Cuadrado M., Ruiz-Arruza I., Brey R., Crowther M., Derksen R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody- positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011, 20:206-218.
105. Hron G., Eichinger S., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Family history for venous thromboembolism and the risk for recurrance. Am J Med 2006, 119:50-53.
106. Simpson E.L., Lawrenson R.A., Nightingale A.L., Farmer R.D. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001, 108:56-60.
107. Larsen T.B., Sorensen H.T., Gislum M., Johnsen S.P. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 2007, 120:505-509.
108. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG 2008, 115:453-461.
109. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008, 6:905-912.
110. Robinson H.E., O'Connell C.M., Joseph K.S., McLeod N.L. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol 2005, 106:1357-1364.
111. Nelson S.M., Greer I.A. Artificial reproductive technology and the risk of venous thromboembolic disease. Haemostasis 2006, 4:1661-1663.
112. Mára M., Koryntová D., Rezábek K., Kaprál A., Drbohlav P., Jirsová S., et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study. Ceska Gynekol 2004, 69:312-316.
113. Rao A.K., Chitkara U., Milki A.A. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report. Hum Reprod 2005, 20:3307-3312.
114. Salomon O., Schiby G., Heiman Z., Avivi K., Sigal C., Levran D., et al. Combined jugular and subclavian vein thrombosis following assisted reproductive technology-new observation. Fertil Steril 2009, 92:620-625.
115. Chan W.S., Dixon M.E. The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008, 121:713-726.
116. Moen V., Dahlgren N., Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004, 101:950-959.
117. Breivik H., Bang U., Jalonen J., Vigfusson G., Alahuhta S., Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand 2010, 54:16-41.
118. Harnett M.J., Walsh M.E., McElrath T.F., Tsen L.C. The use of central neuraxial techniques in parturients with Factor V Leiden mutation. Anesth Analg 2005, 101:1821-1823.
119. Vandermeulen E.P., Van Aken H., Vermylen J. Anticoagulants and spinal- epidural anesthesia. Anesth Analg 1994, 79:1165-1177.
120. Butwick A.J., Carvalho B. Neuraxial anesthesia in obstetric patients receiving anticoagulant and antithrombotic drugs. Int J Obstet Anesth 2010, 19:193-201.
121. Horlocker T.T. What's a nice patient like you doing with a complication like this? Diagnosis, prognosis and prevention of spinal hematoma. Can J Anesth 2004, 51:527-534.
122. Lee L.A., Posner K.L., Domino K.B., Caplan R.A., Cheney F.W. Injuries associated with regional anesthesia in the 1980s and 1990s: a closed claims analysis. Anesthesiology 2004, 101:143-152.
123. Bateman B.T., Mhyre J.M., Ehrenfeld J., Kheterpal S., Abbey K.R., Argalious M., et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the multicenter Perioperative Outcomes Group Research Consortium. Anesth Analg 2013, 116:1380-1385.
124. FDA drug safety communication: updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins 2013, US Food and Drug Administration, US FDA, Silverspring (MD), Accessed on January 30, 2014. November 6, 2013. Available at:. http://www.fda.gov/%20Drugs/DrugSafety/ucm373595.htm.
125. Rodger M. Evidence base for the management of venous thromboembolism in pregnancy. Hematology 2010, 1:173-180.
126. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.O., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005, 132:171-196.
127. James A.H. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007, 120:S26-S34.
128. Required organizational practices handbook 2014 2014, Accreditation Canada, Accreditation Canada, Ottawa, Accessed on February 28, 2014. Available at:. http://www.accreditation.ca/sites/default/files/rop-handbook-%202014-en.pdf.
129. Danilenko-Dixon D.R., Heit J.A., Silverstein M.D., Yawn B.P., Petterson T.M., Lohse C.M.L., et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based case- control study. Am J Obstet Gynecol 2001, 184:104-110.
130. Gibson J.L., Ekevall K., Walker I., Greer I.A. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol 1998, 105:795-797.
131. Burrows R.F., Gan E.T., Gallus A.S., Wallace E.M., Burrows E.A. A randomized double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thromboembolic events after caesarean section: a pilot study. Br J Obstet Gynaecol 2001, 108:835-839.
132. Ellison J., Thomson A.J., Conkie J.A., McCall F., Walker D., Greer I.A. Thromboprophylaxis following caesarean section - a comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinazaparin. Thromb Haemost 2001, 86:1374-1878.
133. Gates S., Brocklehurst P., Ayers S., Bowler U. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low- molecular-weight heparin. Am J Obstet Gynecol 2004, 191:1296-1303.
134. Tooher R., Gates S., Dowswell T., Davis L.J. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2010, 5.
135. Sachdeva A., Dalton M., Amaragiri S.V., Lees T. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2010, 7.
136. Dennis M., Sandercock P.A., Reid J., Graham C., Murray G., Venable G., et al. for the CLOTS Trial Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomized controlled trial. Lancet 2009, 373:1958-1965.
137. Dennis M., Sandercock P.A., Reid J., Graham C., Murray G., Venables G., et al. for the CLOTS Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. Ann Intern Med 2010, 153:553-562.
138. Clarke-Pearson D.L., Creasman W.T., Coleman R.E., Synan I.S., Hinshaw W.M. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984, 18:226-232.
139. Clarke-Pearson D.L., Abaid N. Prevention of venous thromboembolic events after gynecologic surgery. Obstet Gynecol 2012, 119:155-167.
140. James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194:1311-1315.
141. Dekker G.A., de Vries J.I., Doelitzsch P.M., Huijgens P.C., von Blomberg B.M.E., Jakobs C., et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995, 173:1042-1048.
142. Rai R.S., Clifford K., Cohen H., Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995, 10:3301-3304.
143. Kupferminc M.J., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999, 340:9-13.
144. Kupferminc M.J., Fait G., Many A., Gordon D., Eldor A., Lessing J.B. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Am J Obstet Gynecol 2000, 96:45-49.
145. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcomes? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002, 101:6-14.
146. Rey E., Khan S.R., David M., Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003, 361:901-908.
147. Howley H., Walker M., Rodger M. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005, 192:694-708.
148. Wu O., Robertson L., Twaddle S., Lowe G.D., Clark P., Greaves M., et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006, 10:1-110.
149. Rodger M.A., Betancourt M.T., Clark P., Lindqvist P.G., Dizon-Townson D., Said J., et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010, 7.
150. Abou-Nassar K., Carrier M., Ramsay T., Rodger M.A. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011, 128:77-85.
151. Kuttah W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-1589.
152. Rai R., Cohen H., Dave M., Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
153. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
154. Laskin C.A., Spitzer K.A., Clark C.A., Crowther M.R., Ginsberg J.S., Hawker G.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized controlled HepASA trial. J Rheumatol 2009, 36:279-287.
155. Mak A., Cheung M.W., Cheak A.A., Ho R.C. Combination of heparin and aspirin is superior to aspirin alone in enhancing live birth in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010, 49:281-288.
156. Dolitzky M., Inbal A., Segal Y., Weiss A., Brenner B., Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006, 86:362-366.
157. Badawy A.M., Khiary M., Sherif L.S., Hassan M., Ragab A., Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 2008, 28:280-284.
158. Fawzy M., Shokeir T., El-Tatongy M., Warda O., El-Refaiey A.A., Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008, 278:33-38.
159. Clark P., Walker I.D., Langhome P., Crichton L., Thomson A., Greaves M., et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low molecular weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010, 115:4162-4167.
160. Kaandorp S.P., Goddijn M., van der Post J.A., Hutten B.A., Verhoeve H.R., Hamulyak K., et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010, 362:1586-1596.
161. Visser J., Ulander V.-M., Helmerhost F.M., Lampinen K., Morin-Papunen L., Bloemenkamp K.W.M., et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. Thromb Haemost 2011, 105:295-301.
162. Leduc L., Dubois E., Tasker L., Rey E., David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can 2007, 29:787-793.
163. Rey E., Garneau P., David M., Gauthier R., Leduc L., Michon N., et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009, 7:58-64.
164. Gris J.-C., Chauleur C., Faillie J.-L., Baer G., Mares P., Fabbro-Peray P., et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruption placentae (NOH-AP trial). Thromb Haemost 2010, 104:771-779.
165. Gris J.-C., Chaleur C., Molinari N., Mares P., Fabbro-Peray P., Quere I., et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia (NOH-PE trial). Thromb Haemost 2011, 106:1053-1061.
166. Kupferminc M.J., Rimon E., Many A., Maslovitz S., Lessing J.B., Gamzu R. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med 2011, 24:1042-1045.
167. De Vries J.I., van Pampus M.G., Hague W.M., Bezemer P.D., Joosten J.H. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012, 10:64-72. on behalf of FRUIT investigators.
168. Martinelli I., Ruggenenti P., Cetin I., Pardi G., Perna A., Vergani P., et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012, 119:3269-3275.
169. Rodger M.A., Carrier M., Le Gal G., Martinelli I., Perna A., Rey E., et al. Meta-analysis of low molecular weight heparin to prevent recurrent placenta-mediated complications. Blood 2013, 123:822-828.
170. Dodd J.M., McLeod A., Windrim R.C., Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013, 24(7):CD00678.
171. Blanco-Molina A., Trujillo-Santos J., Criado J., Lopez L., Lecumberria R., Guiterrez R., et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007, 97:186-190.
172. Bauersachs R.M., Dudenhausen J., Faridi A., Fischer T., Fung S., Geisen U., et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007, 98:1237-1245.
173. Nelson-Piercy C., Powrie R., Borg J.Y., Rodger M., Talbot D., Stinson J., et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol 2011, 159:293-299.
174. Blanco-Molina A., Rota L., Di Micco P., Brenner B., Trujillo-Santos J., Ruiz-Gamietea A., et al. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost 2010, 103:306-311. for the RIETE Investigators.
175. Clark N.P., Delate T., Cleary S.J., Witt D.M. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy. Thromb Res 2010, 125:402-405.
176. Pabinger I., Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Arterioscler Thromb Vasc Biol 1996, 16:742-748.
177. van Boven H.H., Vandenbroucke J.P., Briet E., Rosendaal F.R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999, 94:2590-2594.
178. Tormene D., Simioni P., Prandoni P., Luni S., Zerbirati P., Sartor D., et al. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica 2001, 86:1305-1309.
179. Gerhardt A., Scharf R.E., Beckmann M.W., Struve S., Bender H.G., Pillny M., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000, 342:374-380.
180. Hiltunen L., Rautanen A., Rasi V., Kaaja R., Kere J., Krusius T., et al. An unfavorable combination of Factor V Leiden with age, weight, and blood group causes high risk of pregnancy-associated venous thrombosis: a population-based nested case-control study. Thromb Res 2007, 119:423-432.
181. Procare G. Risk of venous thromboembolism during pregnancy in homozygous carriers of the Factor V Leiden mutation: are there any predictive factors?. J Thromb Haemost 2004, 2:359-360.
182. Martinelli I., Legnani C., Bucciarelli P., Grandone E., De Stefano V., Mannucci P.M. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001, 86:800-803.
183. Conard J., Horellou M.H., Van Dreden P., Lecompte T., Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990, 63:319-320.
184. Tormene D., De Stefano V., Grandone E., Za T., Perlati M., Rossi M., et al. The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. J Thromb Haemost 2007, 5:2193-2196.
185. Friederich P.W., Sanson B.J., Simioni P., Zanadari S., Huisman M.V., Kindt I., et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996, 125:955-960.
186. Carr M.H., Towers C.V., Eastenson A.R., Pircon R.A., Iriye B.K., Adashek J.A. Prolonged bedrest during pregnancy: does the risk of deep vein thrombosis warrant the use of routine heparin prophylaxis?. J Matern Fetal Med 1997, 6:264-267.
187. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208. Eel W Canadian Task Force on Preventive Health Care.